Eli Lilly, a global pharmaceutical company, has launched Copellor®(Ixekizumab) in India for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis. The drug has been approved by The Drug Controller General of India (DCGI) and is a humanized IgG4 monoclonal antibody that targets IL-17A, a protein responsible for triggering and maintaining inflammation in psoriasis.
According to Vineet Gupta, Managing Director of Eli Lilly and Company – India & India Subcontinent, the impact of psoriasis on a patient’s quality of life is comparable to that of serious diseases such as cancer and heart failure. Copellor®(Ixekizumab) is an innovative medicine that will empower healthcare providers with another option for the treatment of patients with moderate-to-severe plaque psoriasis and psoriatic arthritis, which is a huge unmet need in India.
The drug is available as a prescription medicine in a single strength of 80 mg/ml in a single-dose prefilled autoinjector. However, it should only be used under the advice of a dermatologist or rheumatologist and medical supervision. The availability of Copellor®(Ixekizumab) in India is a significant development in the field of dermatology and a step forward in addressing the unmet needs of patients suffering from psoriasis and psoriatic arthritis.
